BioVie Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
BioVie Inc. (BIVI) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value of $1.58 per share as of 2026-06-30, per its 10-K filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-08-13
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $1.58.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $187.02.
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $116.41.
- 2025-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $10.81.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value as first filed |
|---|---|---|
| 2026-06-30 | $1.58 10-K · filed 2026-08-13 | |
| 2026-03-31 | $187.02 S-1/A · filed 2026-08-06 | |
| 2025-06-30 | $116.41 10-K · filed 2026-08-13 | |
| 2025-03-31 | $10.81 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $13.41 10-Q · filed 2025-02-11 | |
| 2024-09-30 | $46.99 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $445.90 10-K · filed 2026-08-13 | $44.59 10-K · filed 2024-09-30 |
| 2024-03-31 | $4.59 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $4.71 10-Q · filed 2024-02-13 | |
| 2023-09-30 | $5.40 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $524.00 S-1/A · filed 2026-08-06 | $5.24 10-Q · filed 2023-11-08 |
| 2022-06-30 | $16.90 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |